by Team Small News | Jan 27, 2026 | Lupin, Pharma
Lupin, a global pharmaceutical leader, has been recognized for its exceptional sustainability efforts, receiving the highest “A” leadership rating from the Climate Disclosure Project (CDP) for both Climate Change and Water Security. This prestigious... by Team Small News | Jan 25, 2026 | Lupin, Pharma
Lupin, a global pharmaceutical company, has achieved a significant milestone in its sustainability journey by earning a double ‘A’ rating from CDP (formerly known as the Carbon Disclosure Project) for its leadership in climate action and water security.... by Team Small News | Jan 24, 2026 | Lupin, Pharma
Lupin Limited, a global pharmaceutical major, has achieved a significant milestone in its sustainability efforts by receiving the highest ‘A’ leadership rating from the Climate Disclosure Project (CDP) for its exceptional performance in Climate Change and... by Team Small News | Jan 23, 2026 | Lupin, Pharma
Lupin Limited, a global pharmaceutical major, has achieved a significant milestone in its sustainability efforts by receiving the highest ‘A’ leadership rating from the Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change...
by Team Small News | Jan 15, 2026 | Cipla, Lupin, Pharma, Sun Pharma, Zydus
The Indian pharmaceutical industry is bracing for a challenging earnings season in Q3, with expectations of muted margins due to the loss of patent exclusivity for the blockbuster blood cancer drug Revlimid in the US. Revlimid, which has generated over $100 billion in... by Team Small News | Jan 12, 2026 | Lupin, Pharma
Lupin Limited, a global pharmaceutical company, has entered into an exclusive agreement with Gan&Lee Pharmaceuticals of China to commercialize Bofanglutide, a novel GLP-1 receptor agonist, in India. Bofanglutide is a fortnightly treatment for type 2 diabetes and...